ECTIN B Stock Overview
Ectin Research AB, a pharmaceutical company, engages in developing a treatment that eliminates cancer tumors.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Ectin Research AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.37 |
| 52 Week High | kr1.00 |
| 52 Week Low | kr0.29 |
| Beta | 0.90 |
| 1 Month Change | -25.30% |
| 3 Month Change | -27.06% |
| 1 Year Change | -28.46% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -93.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| ECTIN B | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | -5.1% | 4.1% | 2.8% |
| 1Y | -28.5% | 50.2% | 13.6% |
Return vs Industry: ECTIN B underperformed the Swedish Pharmaceuticals industry which returned 50.2% over the past year.
Return vs Market: ECTIN B underperformed the Swedish Market which returned 13.6% over the past year.
Price Volatility
| ECTIN B volatility | |
|---|---|
| ECTIN B Average Weekly Movement | 19.8% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in SE Market | 12.8% |
| 10% least volatile stocks in SE Market | 3.6% |
Stable Share Price: ECTIN B's share price has been volatile over the past 3 months.
Volatility Over Time: ECTIN B's weekly volatility has decreased from 28% to 20% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 1 | Anna-Carin Sjoblom-Hallen | www.ectinresearch.com |
Ectin Research AB, a pharmaceutical company, engages in developing a treatment that eliminates cancer tumors. Its drug candidate MFA-370 that is in Phase I/II clinical trial for the treatment of metastatic urothelial bladder cancer. The company was incorporated in 2013 and is based in Mölndal, Sweden.
Ectin Research AB Fundamentals Summary
| ECTIN B fundamental statistics | |
|---|---|
| Market cap | kr4.72m |
| Earnings (TTM) | -kr17.23m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs ECTIN B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ECTIN B income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr17.23m |
| Earnings | -kr17.23m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 21, 2024
| Earnings per share (EPS) | -1.36 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 17.4% |
How did ECTIN B perform over the long term?
See historical performance and comparison